Published on March 15, 2016
Prof. Denis-Claude Roy, from the Maisonneuve-Rosemont Hospital & Montreal University in Canada, discusses the length of immunotherapy in the context of acute leukemias.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.
This programme has been supported by Pfizer, through an unrestricted educational grant to the Patient Empowerment Foundation
You might also like
Transcript | How long does immunotherapy last?
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.
The immunotherapies are administered over various periods of time. Usually, they're single injections of cells that are modified. For example, in our protocol, we're using cells where we're eliminating those components that react to the patient. This is done on a single injection. However, the patients have to be followed afterwards to make sure that they're doing fine. In their CAR technologies, similarly, it's a single injection of these cells and the patients are being followed afterwards.